
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is leading the way in targeted protein degraders and is well-positioned in the biotechnology industry. With a strong clinical development program and key partnerships with big players like Pfizer and Novartis, they have the potential for significant commercial success. Furthermore, the company's leadership in the LRRK2 pathway and strong biomarker data in their clinical trials showcase their potential for groundbreaking treatments in the future. Overall, their innovative approach to protein degradation and promising results make them a strong buy with potential for long-term growth. However, as with any biotech company, there are standard industry risks that investors should be aware of.
Bears say
Arvinas is a clinical-stage biotechnology company with a focus on developing protein degradation therapeutics for oncology and neurology-related diseases. Despite the potential of its PROteolysis TArgeting Chimera (PROTAC) technology, the company faces challenges in bringing its promising pipeline candidates to market, with only ARV-471 in Phase 2 clinical trials. Additionally, with limited revenue and high research and development expenses, Arvinas may struggle to sustain its operations in the long term.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares